Clinical trials have reported high rates of hyperglycemia in patients treated with AKT/PI3K/mTOR inhibitors, necessitating careful monitoring and management of blood sugar levels in these patients when they are undergoing surgery [26]. The gene discussed is AKT1; the disease is Hyperglycemia.